OCB Physicians are actively involved in research that is advancing the understanding of many conditions that cause blindness. They participate in numerous research studies aimed at improving the medical and surgical care of these conditions, so that we are able to offer better treatment options to our patients.
These pages list active ongoing studies at OCB. Many are enrolling patients. Click on the links below to learn more.
Understanding Clinical Trials
Clinical trials are used to evaluate the safety and effectiveness of medication or medical devices by monitoring their effects on groups of people. They are conducted in a series of steps, called phases. Each phase is designed to answer a separate research question.
- Phase I: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
- Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
- Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
- Phase IV: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use
Jeffrey Heier, MD
Dr. Heier's research interests include new treatments for age related macular degeneration (AMD), diabetic macular edema (DME), and venous occlusive disease (RVO); new vitreoretinal surgical techniques and instrumentation; and diagnostic imaging of the retina. Under Dr. Heier's leadership, OCB has become one of the leading clinical trial centers in the U.S. for novel treatments for retinal diseases. Over the past 15 years, these therapies have dramatically improved the outlook for patients with AMD, DME, RVO and other retinal diseases. Research Coordinator : Alison Nowak 617-314-2694
Michael Raizman, MD
Dr. Raizman’s research interests include treatments for conditions that affect the cornea. A primary focus of his is corneal collagen crosslinking, a groundbreaking therapy for patients diagnosed with keratoconus, which recently received FDA approval. He also investigates new less invasive alternative procedures to cornea transplant, novel surgical advances in cataract surgery, new developments in laser technology, and treatments for Fuchs Dystrophy.
Click here to learn more about the studies Dr. Raizman is participating in.
Research Coordinator :
Joanne Berry 617-314-2703
Peter Rapoza, MD
Dr. Rapoza is a recognized authority in the field of corneal and cataract surgery, refractive surgery and the medical and surgical treatment of the cornea and ocular surface. He has earned an international reputation as a skilled ophthalmologist who uses advanced technologies to provide his patients with the finest ocular care available. His research interests include radial and astigmatic keratotomy, photorefractive keratectomy (PRK). LASIK, corneal transplantation and cataract surgery He has participated in numerous clinical trials for ophthalmic pharmaceutical agents for the treatment of corneal transplant rejection, ocular inflammation in cataract surgery, dry eye and ocular infections.
Click here to learn more about the studies Dr. Rapoza is participating in.
Joanne Berry, 617-314-2778
Lana Rifkin, MD
Dr. Rifkin is one of a few ophthalmologists in the country who specializes in uveitis (ocular inflammatory diseases) and her clinical research is focused on this condition and its consequences. She has published many peer-reviewed research papers and book chapters, serves as a reviewer for several esteemed journals, and is a frequent presenter at local, regional and national conferences.
Click here to learn more about the studies Dr. Rifkin is participating in.
Research Coordinator :
Joanne Berry, 617-314-2702
Jason Rothman, MD
Dr. Rothman is a dry eye specialist with special research interests in complex dry eye and external eye disease. He has conducted clinical research into dry eye, blepharitis and allergic conjunctivitis. He has been published in multiple medical journals and has also written book chapters on corneal transplant complications and allergic conjunctivitis.
Click here to learn more about the studies Dr. Rothman is participating in.
Research Coordinator :
Amanda Campbell 617-314-2778
Chirag Shah, MD, MPH
Dr. Shah's research interests cover a myriad of retinal conditions, including macular degeneration, retinal vein occlusion, diabetic retinopathy, and retinal detachment. he has published in mulitiple peer-reviewed journals and serves as the Deputy Editor of the American Academy of Ophthalmology's ONE Network, a platform that educates 30,000 ophthalmologists worldwide. He is the Editor of the Clinical Trials section of Retina Times and a Co-Editor of the Wills Eye Five Minute Consult.
Click here to learn more about the studies Dr. Shah is participating in.Research Coordinator : Alison Nowak 617-314-2694